MedTrace Logo

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-12-15

No results posted yet for this study

Summary

The purpose of this study is to examine how a single dose of MIFEPREX® (mifepristone) affects the breast tissue in patients with BRCA1 (a gene that normally acts to restrain the growth of cells in the breast, but if it mutates may lead to breast cancer) mutations undergoing a planned prophylactic mastectomy (having one or both breasts removed).

Conditions

  • BRCA1 Mutation
  • High-grade Serous Ovarian Cancer
  • TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

Mifepristone 200 MG

Orally, one time dosage of 200 mg

PROCEDURE

Prophylactic mastectomy

Planned prophylactic mastectomy (having one or both breasts removed).

Sponsors & Collaborators

  • Breast Cancer Research Foundation

    collaborator OTHER

  • Indiana University

    lead OTHER

Principal Investigators

  • Tarah Ballinger, MD · Indiana University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062174 on ClinicalTrials.gov